Tourmaline Bio (TRML) is hosting its Investor Day. Tourmaline today is announcing the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Tourmaline expects to report topline data from this trial in the second quarter of 2025. Expansion of Cardiovascular Scientific Advisory Board, SAB, with two new appointments: Deepak L. Bhatt; Dipender Gill.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML: